Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.58 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.57 |
| ▸ | CTSB | P07858 | 3/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5563236 | 1.00 | CAPN1 (0.58) | CAPN1CTRB1CTSBACE | |
| SCHEMBL2269431 | 1.00 | CAPN1 (0.58) | CAPN1CTRB1CTSBACE | |
| SCHEMBL12290446 | 0.87 | CAPN1 (0.56) | CAPN1CTSBACE | |
| SCHEMBL3292711 | 0.86 | CAPN1 (0.61) | CAPN1CTSBACE | |
| SCHEMBL17865652 | 0.86 | CAPN1 (0.61) | CAPN1CTSBACE | |
| SCHEMBL2369340 | 0.86 | CAPN1 (0.61) | CAPN1CTSBACE | |
| SCHEMBL2270660 | 0.85 | ACACB (0.54) | CAPN1CTRB1CTSB | |
| SCHEMBL2268108 | 0.85 | ESR1 (0.47) | CAPN1CTSB | |
| SCHEMBL7796543 | 0.85 | CTRB1 (0.59) | CTRB1 | |
| SCHEMBL14542450 | 0.85 | CAPN1 (0.43) | CAPN1CTRB1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | VOYAGER PHARMACEUTICAL CORPORATION (US) | 2011-08-11 | — | — | US | claimed |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | VOYAGER PHARMACEUTICAL CORPORATION | 2008-07-17 | — | — | US | claimed |
| EP-0683792-B1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LAB (US) | 2001-09-26 | — | — | EP | claimed |
| EP-1047690-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2000-11-02 | — | — | EP | claimed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | claimed |
| EP-0673254-A4 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| EP-0683792-A4 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6. | ABBOTT LAB (US) | 1998-11-18 | — | — | EP | claimed |
| US-5698522-A | INHIBIT RELEASE OF LUTEINIZING HORMONE RELEASING HORMONE | ABBOTT LABORATORIES (US) | 1997-12-16 | — | — | US | claimed |
| JP-H08505611-A | — | — | 1996-06-18 | — | — | JP | claimed |
| JP-H08504209-A | — | — | 1996-05-07 | — | — | JP | claimed |
| EP-0683792-A1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LABORATORIES (US) | 1995-11-29 | — | — | EP | claimed |
| EP-0673254-A1 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1995-09-27 | — | — | EP | claimed |
| WO-1994014841-A1 | LHRH ANTAGONISTS HAVING MODIFIED AMINOACYL RESIDUES AT POSTIONS 5 AND 6 | ABBOTT LABORATORIES (US) | 1994-07-07 | — | — | WO | claimed |
| WO-1994013313-A1 | 6-POSITION MODIFIED DECAPEPTIDE LHRH ANTAGONISTS | ABBOTT LABORATORIES (US) | 1994-06-23 | — | — | WO | claimed |
| US-5110904-A | Luteinizing hormone releasing hormone; suppression of sex hormones | ABBOTT LABORATORIES (US) | 1992-05-05 | — | — | US | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195898-A1 | TREATMENT OF ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT USING GNRH-I ANALOGS AND ONE OR MORE OF ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONISTS | GNRHR, GRIN1, GRIN3A | CAPN1 1240/4885CTRB1 2031/4885CTSB 464/4885 |
| US-20080171736-A1 | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists | GNRHR, GRIN1, GRIN3A | CAPN1 1240/4885CTRB1 2031/4885CTSB 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.